The company announced Wednesday that the first participant had received a dose. Earlier this week, competitor Pfizer began a similar study of its own reformulated shots.
This version of the coronavirus, which scientists call BA.2, is widely considered stealthier than the original version of Omicron because particular genetic traits make it somewhat harder to detect. Some scientists worry it could also be more contagious.
The researchers spoke with 12 doctors who’d practices in small northern communities in the past five years, but who’d since decided to close up shop and leave.
At this point in the pandemic (more than six months after most Canadian adults became eligible to receive a COVID-19 vaccine), should we declare this level of vaccination coverage as the “vaccine ceiling?”
The new U.S. study is enrolling up to 1,420 healthy adults, ages 18 to 55, to test the updated Omicron-based shots for use as a booster or for primary vaccinations.
